Dr. Andy

Reflections on medicine and biology among other things

Monday, March 07, 2005

More Free Market Health Care

Pfizer is planning on selling its potentilal blockbuster new drug, torcetrapib, raises the level of "good" high-density cholesterol only in combination with Lipitor, it's statin. Statin's lower LDL, the bad cholesterol.

Not coincidentally, Lipitor will soon go generic.

I think these kinds of shenanigans are more a result of a distorted market, than a problem of a market based approaced to health care (and pharmaceuticals in particular)

As the article puts it:

When the F.D.A. reviews a new medicine, its main concerns are safety and
efficacy. The agency has little authority over the cost of new drugs or
ability to encourage competition among drug companies.
Maybe that should change.

1 Comments:

At 2:02 PM, Anonymous Anonymous said...

Lipitor doesn't lose patent protection for quite a while, actually. It's complicated, but 5-7 years at the minimum. Longer if it gets a new indications

 

Post a Comment

<< Home